Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

Recruiting

I'm Interested

Trial ID: NCT03680781

Purpose

This study evaluates the effectiveness of re-treatment using accelerated schedule of intermittent theta-burst stimulation for treatment-resistant depression. This is an open label study.

Official Title

Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study

Stanford Investigator(s)

Ian H. Kratter, MD, PhD
Ian H. Kratter, MD, PhD

Clinical Assistant Professor, Psychiatry and Behavioral Sciences

Nolan Williams
Nolan Williams

Associate Professor of Psychiatry and Behavioral Sciences (Major Laboratories & Clinical Translational Neurosciences Incubator) and, by courtesy, of Radiology (Neuroimaging and Neurointervention)

Eligibility


Inclusion Criteria:

   - Male or female, 18 to 75 years of age.

   - Able to provide informed consent.

   - Diagnosed with Major Depressive Disorder (MDD) or bipolar affective disorder 2 and
   currently experiencing a Major Depressive Episode (MDE).

   - prior exposure to rTMS

   - Participants must qualify as "moderate or severe treatment refractory" using the
   Maudsley staging method.

   - Participants may continue antidepressant regimen, but must be stable for 6 weeks prior
   to enrollment in the study. They must maintain that same antidepressant regimen
   throughout the study duration.

   - Participants are required to have a stable psychiatrist for the duration of study
   enrollment.

Exclusion Criteria:

   - History of MI, CABG, CHF, or other cardiac history

   - Any neurological conditions

   - History of epilepsy

   - OCD

   - Independent sleep disorder

   - Autism Spectrum Disorder

Intervention(s):

device: Intermittent theta-burst stimulation (iTBS)

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Claudia Tischler, BA
650-498-8535